Warwick Smith, director general of the British Generic Manufacturers Association, has warned of increased costs and risks to the NHS due to intellectual property requirements sought by the US as part of a free trade agreement with the UK.
Any potential trade deal with the US must not put the UK’s National Health Service at risk, the British Generic Manufacturers Association has insisted.
Amidst the ongoing chaos of Brexit negotiations as well as US president Donald Trump’s visit to the UK this week,...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
